about
Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapyAnti-angiogenic therapies for metastatic colorectal cancer: current and future perspectivesRole of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinomaAngiogenesis Inhibitors for the Treatment of Hepatocellular CarcinomaRegorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis.Regorafenib: an evidence-based review of its potential in patients with advanced liver cancerp38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance.Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer.Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.Reversibility of regorafenib effects in hepatocellular carcinoma cells.Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models.Overcoming resistance to antiangiogenic therapies.Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy.Role of targeted agents in metastatic colorectal cancer.Novel drug discovery opportunities for colorectal cancer.Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis.The preclinical development of regorafenib for the treatment of colorectal cancer.Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.Novel drugs in clinical development for hepatocellular carcinoma.Regorafenib for the treatment of unresectable hepatocellular carcinoma.Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study.Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies.Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literatureMulti-kinase inhibition in ovarian cancer.The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells.Incidence and risk of regorafenib-induced hepatotoxicity.Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species.Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib.Disrupting Tumor Angiogenesis and "the Hunger Games" for Breast Cancer.Topical administration of regorafenib eye drops: Phase I dose-escalation study in healthy volunteers.Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.Comparison of the crystal structures of the potent anticancer and anti-angiogenic agent regorafenib and its monohydrate.
P2860
Q26745418-8E710678-3198-4C2A-B1FD-0F1AA9DA5915Q26826817-4B00C5BD-E980-45F2-92FF-D32CB6BD0E83Q28070762-794E92F9-15CB-48A0-9832-E41222B9E61CQ28075305-16C930E8-56AD-4F9E-9E16-9BF8D8A98386Q30593460-D68D27A3-05CA-4E55-9F9D-B24409B8F95CQ33838524-99F5A77E-7C91-42F3-A4B5-EC3DE6527FFEQ33944599-E8EB7971-77AF-4551-9DA3-2E3D6B37138BQ34008781-20F59367-67BE-44BD-9E25-D34A744C93CCQ36177646-5B41B057-C8C0-4A1E-9BA7-8548DFA88BE1Q36570837-43BC6A09-6375-4816-9353-A9D87DD09CD4Q37332505-F67C236D-B054-4BC1-8ED8-53831D7BD59BQ37429966-5997F288-630C-4424-9DE2-459B4DDA97BEQ38024765-58D00C6E-07B7-4E2F-9B30-BB0B7FC7847CQ38097519-F1051AA5-56BE-483B-8E7F-9173069AF99EQ38104294-DB5A53EC-606F-4F09-8DE6-4C81C984B6C3Q38114502-C60593AB-C132-43BB-A126-9F1CC6C52323Q38154815-3F582221-5823-490B-A9C0-ABBB094F62C6Q38217516-E752C43E-2D20-4F5D-83B9-ED7D17000014Q38496239-D235E7A7-9270-4539-8EBE-E816B123070DQ38537138-34D125EF-0A17-4B7A-8AD7-A1C7DDAE64D0Q38674803-CC0E6348-EFE0-4C94-852D-4A91D460313BQ38805622-06A4714C-C3DF-4E39-8318-6EB115D90DB6Q39458547-C574B6FD-9549-46A0-A81E-F534048F3008Q41339309-52CDF484-956F-4903-A01A-18B9B2B487A3Q42427413-25440134-BD00-43BB-864E-D55CB63A54A6Q42434225-F191F720-D526-4316-8CB8-61C492D5B513Q45800216-878065D0-A043-42CC-AFE8-A3667D408BA5Q46238888-C44CCE5E-6E0F-45DA-80EE-EE5ACCB6B12DQ47138737-8BC8A990-8439-4932-BCAB-76CC2653C673Q49544357-AD20A8F6-BE28-4670-8D3D-E9834DB621C0Q50119662-0ABFB039-4891-41AF-9EF5-CB8289E9313FQ50968798-8A04783C-8A77-48C0-A750-815B321C4EBFQ55025851-CF4FD55B-CE9B-431C-90D7-C50302CBE625
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Regorafenib for cancer.
@ast
Regorafenib for cancer.
@en
Regorafenib for cancer.
@nl
type
label
Regorafenib for cancer.
@ast
Regorafenib for cancer.
@en
Regorafenib for cancer.
@nl
prefLabel
Regorafenib for cancer.
@ast
Regorafenib for cancer.
@en
Regorafenib for cancer.
@nl
P2860
P1476
Regorafenib for cancer.
@en
P2093
Beate Schultheis
Dirk Strumberg
P2860
P304
P356
10.1517/13543784.2012.684752
P407
P577
2012-06-01T00:00:00Z